Trial
NCT00381810
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Lupus Erythematosus, Systemic
Intervention
Rituximab
Why stopped
During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-01